000075613 001__ 75613
000075613 005__ 20190709135535.0
000075613 0247_ $$2doi$$a10.1093/jac/dkx325
000075613 0248_ $$2sideral$$a104800
000075613 037__ $$aART-2017-104800
000075613 041__ $$aeng
000075613 100__ $$aArana, D.M.
000075613 245__ $$aCarbapenem-resistant Citrobacter spp. isolated in Spain from 2013 to 2015 produced a variety of carbapenemases including VIM-1, OXA-48, KPC-2, NDM-1 and VIM-2
000075613 260__ $$c2017
000075613 5060_ $$aAccess copy available to the general public$$fUnrestricted
000075613 5203_ $$aObjectives: There is little information about carbapenemase-producing (CP) Citrobacter spp.We studied the molecular epidemiology and microbiological features of CP Citrobacter spp. isolates collected in Spain (2013-15).
Methods: In total, 119 isolates suspected of being CP by the EUCAST screening cut-off values were analysed. Carbapenemases and ESBLs were characterized using PCR and sequencing. The genetic relationship among Citrobacter freundii isolates was studied by PFGE.
Results: Of the 119 isolates, 63 (52.9%) produced carbapenemases, of which 37 (58.7%) produced VIM-1, 20 (31.7%) produced OXA-48, 12 (19%) produced KPC-2, 2 (3.2%) produced NDM-1 and 1 (1.6%) produced VIM- 2; 9 C. freundii isolates co-produced VIM-1 plus OXA-48. Fourteen isolates (22.2%) also carried ESBLs: 8 CTX-M-9 plus SHV-12, 2 CTX-M-9, 2 SHV-12 and 2 CTX-M-15. Fifty-seven isolates (90.5%) were C. freundii, 4 (6.3%) were Citrobacter koseri, 1 (1.6%) was Citrobacter amalonaticus and 1 (1.6%) was Citrobacter braakii. By EUCAST breakpoints, eight (12.7%) of the CP isolates were susceptible to the four carbapenems tested. In the 53 CP C. freundii analysed by PFGE, a total of 44 different band patterns were observed. Four PFGE clusters were identified: cluster 1 included eight isolates co-producing VIM-1 and OXA-48; blaVIM-1 was carried in a class 1 integron (intI-blaVIM-1 - aacA4-dfrB1-aadA1-catB2-qacE¿1/sul1) and blaOXA-48 was carried in a Tn1999.2 transposon.
Conclusions: We observed the clonal and polyclonal spread of CP Citrobacter spp. across several Spanish geographical areas. Four species of Citrobacter spp. produced up to five carbapenemase types, including coproduction of VIM-1 plus OXA-48. Some CP Citrobacter spp. isolates were susceptible to the four carbapenems tested, a finding with potential clinical implications.
000075613 536__ $$9info:eu-repo/grantAgreement/ES/MINECO-ISCIII/PY1135-16
000075613 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000075613 590__ $$a5.217$$b2017
000075613 591__ $$aINFECTIOUS DISEASES$$b8 / 88 = 0.091$$c2017$$dQ1$$eT1
000075613 591__ $$aPHARMACOLOGY & PHARMACY$$b19 / 261 = 0.073$$c2017$$dQ1$$eT1
000075613 591__ $$aMICROBIOLOGY$$b19 / 125 = 0.152$$c2017$$dQ1$$eT1
000075613 592__ $$a2.419$$b2017
000075613 593__ $$aInfectious Diseases$$c2017$$dQ1
000075613 593__ $$aPharmacology (medical)$$c2017$$dQ1
000075613 593__ $$aPharmacology$$c2017$$dQ1
000075613 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000075613 700__ $$aOrtega, A.
000075613 700__ $$aGonzález-Barberá, E.
000075613 700__ $$aLara, N.
000075613 700__ $$aBautista, V.
000075613 700__ $$aGómez-Ruíz, D.
000075613 700__ $$aSáez, D.
000075613 700__ $$aFernández-Romero, S.
000075613 700__ $$aAracil, B.
000075613 700__ $$aPérez-Vázquez, M.
000075613 700__ $$aCampos, J.
000075613 700__ $$aOteo, J.
000075613 700__ $$aGómez-Alfaro, I.
000075613 700__ $$aAznar, J.E.
000075613 700__ $$aCercenado, E.
000075613 700__ $$aLópez-Urrutia, L.
000075613 700__ $$aGarcía-Picazo, L.
000075613 700__ $$aLópez-Calleja, A.I.
000075613 700__ $$aSánchez-Romero, I.
000075613 700__ $$aZamarrón-Fuertes, P.
000075613 700__ $$aLeiva, J.
000075613 700__ $$aAlós, J.I.
000075613 700__ $$aSolís, S.
000075613 700__ $$ade Miguel, M.D.
000075613 700__ $$aHernández, B.
000075613 700__ $$aRomanyk, J.
000075613 700__ $$aDelgado-Iribarren, A.
000075613 700__ $$aFernández, E.O.
000075613 700__ $$aTrujillo, G.
000075613 700__ $$aTorroba, L.
000075613 700__ $$aHernández Almaraz, J.L.
000075613 700__ $$aRemacha Esteras, M.A.
000075613 700__ $$aSalso, S.
000075613 700__ $$aGil, Y.
000075613 700__ $$aRodríguez-Conde, I.
000075613 700__ $$aAlarcón, T.
000075613 773__ $$g72, 12 (2017), 3283-3287$$pJ. antimicrob. chemother.$$tJournal of Antimicrobial Chemotherapy$$x0305-7453
000075613 8564_ $$s308114$$uhttps://zaguan.unizar.es/record/75613/files/texto_completo.pdf$$yVersión publicada
000075613 8564_ $$s119376$$uhttps://zaguan.unizar.es/record/75613/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000075613 909CO $$ooai:zaguan.unizar.es:75613$$particulos$$pdriver
000075613 951__ $$a2019-07-09-12:04:43
000075613 980__ $$aARTICLE